By Sabela Ojea

Allergy Therapeutics PLC said that it has received clearance for an investigational new drug application from the U.S. Food & Drug Administration for its peanut allergy vaccine.

The commercial biotechnology company specializing in allergy vaccines said this clearance paves the way for the first phase Protect trial, to be launched in the U.S.

The trial will begin later this year, Chief Executive Manuel Llobet said.

Shares at 0802 GMT were up 1.50 pence, or 6.3%, at 25.25 pence.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

January 26, 2022 03:30 ET (08:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergy Therapeutics Charts.